Several matter pinch shares of Nokia Corporation (NYSE:NOK) [Trend Analysis], as shares moving down -0.96% to $5.18 with a share volume of 8.47 Million. Nokia (NOK) took the centre stage at MWC 2017 to unveil its new smartphones Nokia 3 and Nokia 5 in Barcelona. However, the company did disappoint several consumers who were anticipating the announcement of a flagship smartphone. A new rumour has now suggested that a flagship Nokia smartphone with Snapdragon 835 SoC will be reported by the company in June and will be made accessible in two size variants.
As per the new rumour by Chinese site MyDrivers, the Nokia flagship smartphone will be made accessible with two memory options, 4GB and 6GB of RAM, and will be powered by a Snapdragon 835 SoC, as pointed out in a report by PocketNow. The phone is expected to come with unibody metal design and even though the display size has not been mentioned, the flagship smartphone has been tipped to come in two screen sizes.In terms of optics, the Nokia flagship device has been tipped to come with “at least” 23-megapixel primary camera setup, as per the report. Interestingly, it has been suggested that at least one of the two variants will be sporting a dual-camera setup. The stock is going forward its 52-week low with 28.22% and moving down from its 52-week high price with -13.52%. The float short ratio was 0.55%, as compared to sentiment indicator; Short Ratio was 2.42.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) [Trend Analysis] has commenced the commercial launch of the precision medicine Galafold in Italy following the final publication of reimbursement guidelines by the Ministry of Health (Ministerodella Salute). Galafold is now reimbursed in Italy as a therapy for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidaseA deficiency) and who have an amenable mutation.
“The commercial launch of Galafold in Italy is a important milestone for the Fabry community,” stated John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. “All Fabry patients in Italy 16 years and older who have an amenable mutation will now have access to the first oral treatment as well as the first precision medicine for their Fabry disease. We believe that our successful pricing and reimbursement in Italy is a testament to the important value of our oral precision medicine, and reflects our growing momentum with the country-by-country processes to launch Galafold throughout the EU.”